Live feed07:00:00·486dPRReleasevia QuantisnowSenti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AMLByQuantisnow·Wall Street's wire, on your screen.SNTI· Senti Biosciences Inc.Health Care
